세계의 종양괴사인자(TNF) 억제제 시장 보고서(2023년)

“Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor necrosis factor inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor necrosis factor inhibitor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The tumor necrosis factor inhibitor drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product Type: Humira; Enbrel; Remicade; Simponi/Simponi Aria; Cimzia; Biosimilars

• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection

• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

• 4) By Application: Rheumatoid Arthritis; Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Juvenile Idiopathic Arthritis; Hidradenitis Suppurativa; Other Applications

• Companies Mentioned: AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services Inc.; UCB S.A.; Novartis International AG

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the tumor necrosis factor inhibitor drugs market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Merck & Co.Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Sanofi S.A, Celltrion Inc., HanAll Biopharma, AstraZeneca plc, ACROBiosystems, and Alomone Labs.

The global tumor necrosis factor inhibitor drugs market is expected to grow from $41.23 billion in 2022 to $41.84 billion in 2023 at a compound annual growth rate (CAGR) of 1.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor necrosis factor inhibitor drugs market is expected to reach $43.88 billion in 2027 at a CAGR of 1.2%.

The tumour necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Tumour necrosis factor (TNF) inhibitor drugs refer to drugs that help stop inflammation. TNF inhibitors are used to treat inflammatory and autoimmune illnesses by suppressing the inflammatory response generated by TNF cytokines.

North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumour necrosis factor (TNF) inhibitors drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types in the market of tumour necrosis factor (TNF) inhibitor drugs are humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. Humira refers to a tumour necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. The route of administration is subcutaneous injection, intravenous injection. The distribution channels involved hospital pharmacies, retail pharmacies, and online pharmacies, that are to be used in rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa and others.

The increasing prevalence of autoimmune illness is expected to propel the growth of the tumor necrosis factor inhibitor drugs market going forward. Autoimmune disorders are conditions in which the immune system of the body unintentionally targets and kills healthy human tissue. The tumor necrosis factor inhibitor drug is used in autoimmune disorders to stop inflammation if there is any pain or swelling or illness, these drugs block the action. It gives a booster to the immune system, makes it steady, and protects the body from inflammation. For instance, in June 2022, according to the Autoimmune Association, a US-based non-profit organization dedicated to autoimmune disease awareness, 4.7 million US men suffered from autoimmune disease 2022, representing 20% of all autoimmune disease patients. 31 million US people suffer 80-150 unique autoimmune diseases in 2022, it's expected to increase in the future. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the tumor necrosis factor inhibitor drugs market.

Product innovations are a key trend in gaining popularity in the tumor necrosis factor inhibitor drugs market. Major companies operating in the tumor necrosis factor inhibitor drugs market are focused on developing innovative products to strengthen their position in the market. For instance, in December 2021, Pfizer Inc, a US-based company operating in tumor necrosis factor inhibitor drugs, launched XELJANZ. XELJANZ is intended to treat ankylosing spondylitis in those who haven't responded well to one or more TNF blockers. It has a unique treatment option for 'ankylosing spondylitis'(SA) that does not require an injection or an infusion to treat this debilitating and chronic immuno-inflammatory disease. XELJANZ works by blocking the action of Janus kinase enzymes, which are involved in inflammation.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsungbioepis Co.Ltd. for $2.3 billion. Through this acquisition, Samsung Biologics is expected to accelerate Samsung Bioepis' biosimilar development capabilities and future performance in novel drug development, with improved autonomy and agility in business operations. Samsung bioepis Co.Ltd. is a South Korea-based biopharmaceutical company operating in tumor necrosis factor inhibitor drugs.

The countries covered in the tumour necrosis factor (TNF) inhibitors drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The tumour necrosis factor (TNF) inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides tumour necrosis factor (TNF) inhibitor drugs market statistics, including global market size, regional shares, competitors with a tumour necrosis factor (TNF) inhibitor drugs market share, detailed tumour necrosis factor (TNF) inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumour necrosis factor (TNF) inhibitor drugs industry. This tumour necrosis factor (TNF) inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Tumor Necrosis Factor Inhibitor Drugs Market Characteristics

3. Tumor Necrosis Factor Inhibitor Drugs Market Trends And Strategies

4. Tumor Necrosis Factor Inhibitor Drugs Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Tumor Necrosis Factor Inhibitor Drugs Market
• 4.2. Ukraine-Russia War Impact On Tumor Necrosis Factor Inhibitor Drugs Market
• 4.3. Impact Of High Inflation On Tumor Necrosis Factor Inhibitor Drugs Market

5. Tumor Necrosis Factor Inhibitor Drugs Market Size And Growth

• 5.1. Global Tumor Necrosis Factor Inhibitor Drugs Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Tumor Necrosis Factor Inhibitor Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Tumor Necrosis Factor Inhibitor Drugs Market Segmentation

• 6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Humira
• Enbrel
• Remicade
• Simponi/Simponi Aria
• Cimzia
• Biosimilars
• 6.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Subcutaneous Injection
• Intravenous Injection
• 6.3. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Other Applications

7. Tumor Necrosis Factor Inhibitor Drugs Market Regional And Country Analysis

• 7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market

• 8.1. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Tumor Necrosis Factor Inhibitor Drugs Market

• 9.1. China Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 9.2. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Tumor Necrosis Factor Inhibitor Drugs Market

• 10.1. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Tumor Necrosis Factor Inhibitor Drugs Market

• 11.1. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Tumor Necrosis Factor Inhibitor Drugs Market

• 12.1. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market

• 13.1. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Tumor Necrosis Factor Inhibitor Drugs Market

• 14.1. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market

• 15.1. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 15.2. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Tumor Necrosis Factor Inhibitor Drugs Market

• 16.1. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Tumor Necrosis Factor Inhibitor Drugs Market

• 17.1. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Tumor Necrosis Factor Inhibitor Drugs Market

• 18.1. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market

• 19.1. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 19.2. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Tumor Necrosis Factor Inhibitor Drugs Market

• 20.1. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Tumor Necrosis Factor Inhibitor Drugs Market

• 21.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 21.2. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Tumor Necrosis Factor Inhibitor Drugs Market

• 22.1. USA Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 22.2. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Tumor Necrosis Factor Inhibitor Drugs Market

• 23.1. South America Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 23.2. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Tumor Necrosis Factor Inhibitor Drugs Market

• 24.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Tumor Necrosis Factor Inhibitor Drugs Market

• 25.1. Middle East Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 25.2. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Tumor Necrosis Factor Inhibitor Drugs Market

• 26.1. Africa Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 26.2. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape And Company Profiles

• 27.1. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape
• 27.2. Tumor Necrosis Factor Inhibitor Drugs Market Company Profiles
  • 27.2.1. AbbVie Inc.
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Amgen Inc.
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Johnson & Johnson Services Inc.
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. UCB S.A.
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Novartis International AG
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Tumor Necrosis Factor Inhibitor Drugs Market

29. Tumor Necrosis Factor Inhibitor Drugs Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer